Tiziana Life Sciences PLC Director/PDMR Shareholding (0849O)

TIDMTILS

RNS Number : 0849O

Tiziana Life Sciences PLC

05 February 2021

PDMR DEALING

5 February 2021

NEW YORK and LONDON - February 5, 2021 (GLOBE NEWSWIRE) - Tiziana Life Sciences plc (NASDAQ: TLSA / LSE: TILS) ("Tiziana" or the "Company"), a biotechnology company focused on innovative therapeutics for oncology, inflammation, and infectious diseases, today announces the following option award in connection with the appointment of Dr Thomas Adams, Ph.D. as an executive director.

The Board, on the recommendation of the Remuneration Committee, have granted Dr Adams 3,500,000 options under the Company's share option plan. 3,000,000 of the options vest over a 4 year period in equal tranches and have an exercise price of 149 pence per share. The balance of 500,000 options vest on the attainment of clinical milestones relating to the Company's oncology programs with the same exercise price.

The notifications below, made in accordance with the requirements of the UK Market Abuse Regulation, provides further detail.

 
1.  Details of PDMR / person closely associated 
a)  Name                  Dr Thomas Adams 
2.  Reason for the notification 
a)  Position              Director, Head of Drug Development 
     / status 
b)  Initial notification  Initial notification 
     /amendment 
3.  Details of the issuer 
a)  Name                  Tiziana Life Sciences plc 
b)  LEI                   213800CED47HI8PIOB36 
4.  Details of the transaction(s): section to be repeated for 
     (i) each type of instrument; (ii) each type of transaction; 
     (iii) each date; and (iv) each place where transactions have 
     been conducted 
a)  Description           Ordinary Shares of 3 pence each 
     of the financial 
     instrument 
b)  Identification        ISIN for Tiziana Life Sciences plc: GB00BKWNZY55 
     code of the 
     Financial 
     Instrument 
c)  Nature of             Grant of options 
     the transaction 
d)  Price(s)              Price  Volume 
     and volume(s)         149p   3,500,000 
f)  Date of the           2 February 2021 
     transaction 
 
g)  Place of              XLON 
     the transaction 
 

About Tiziana Life Sciences

Tiziana Life Sciences plc is a UK biotechnology company that focuses on the discovery and development of novel molecules to treat human disease in oncology and immunology. In addition to Milciclib, the Company is also developing Foralumab for liver diseases. Foralumab is the only fully human anti-CD3 monoclonal antibody in clinical development in the world. This Phase 2 compound has potential application in a wide range of autoimmune and inflammatory diseases, such as nonalcoholic steatohepatitis (NASH), ulcerative colitis, multiple sclerosis, type-1 diabetes (T1D), Crohn's disease, psoriasis and rheumatoid arthritis, where modulation of a T-cell response is desirable. The company is accelerating development of anti-Interleukin 6 receptor (IL6R) mAb, a fully human monoclonal antibody for treatment of IL6-induced inflammation, especially for treatment of COVID-19 patients.

For further enquiries:

United Kingdom Investors:

 
Tiziana Life Sciences plc 
 Gabriele Cerrone, Chairman and founder   [phone] 
 

U.S. Investor Contact:

RedChip Companies, Inc.

Dave Gentry

407-491-4498

[e-mail]

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DSHDDGDDRGGDGBS

(END) Dow Jones Newswires

February 05, 2021 02:10 ET (07:10 GMT)